Adventrx Pharmaceuticals, Inc.
Gastrointestinal cancer drug developer records loss of $0.06 per share
Published in Pharma Investments, Ventures and Law Weekly, December 18th, 2005
Adventrx reported a net loss of $3.5 million, or $0.06 per share, for the third quarter of 2005, compared with a net loss of $2.1 million, or $0.04 per share, for the third quarter of 2004.
"In the third quarter Adventrx experienced increased visibility to the investment community with the company's selection to the new Russell Microcap Index and with a $20 million private equity placement led by Carl Icahn," said Evan M. Levine, Adventrx president and chief executive officer. "We increased the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- A.P. Pharma, Inc.
Developer of polymer-based drug delivery systems evaluating financing options - Aastrom Biosciences, Inc
Stem cell therapy developer reports net loss of $0.03 per share - Aceto Corp.
Chemically derived drug maker reports $5.4M decline in sales - Acusphere, Inc.
Microparticle drug developer reports on operational progress - Advanced BioPhotonics, Inc.
Medical imaging developer obtains $4M financing - Advanced Magnetics, Inc.
Nanotechnology company reports loss of $0.36 per share - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
